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ABSTRACT 
 
The incidence and prevalence of Crohn's disease is increasing, particularly in the Western 
world and Asia. Corticosteroids have been used for decades to treat active Crohn’s disease 
and remain the mainstay in management of moderate-to severe relapses in Crohn's disease. 
Use of corticosteroids, despite their efficacy, may be associated with several drawbacks.  
This review article provides a comprehensive account of the role of corticosteroids in 
inducing remission in adult patients with Crohn's disease including aspects such as 
approaches to steroid-sparing and to minimize the risk of steroid dependency, as well as the 
role of newer corticosteroids such as budesonide in reducing systemic side effects.  
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INTRODUCTION 
Crohn’s disease (CD) is a life-long chronic inflammatory condition, which is characterized by 
repetitive flares and periods of inactive disease. Its relapsing behaviour frequently 
necessitates a combination of approaches to effectively treat active disease. In clinical 
practice, active CD is defined by the presence of symptoms such as chronic or nocturnal 
diarrhea, abdominal pain, and rectal bleeding (1); in clinical trials disease activity is 
measured by a CD Activity Index (CDAI) score ≥ 150 (2, 3). One challenging goal in the 
therapy of CD flares is to induce remission in active CD. Several agents are available for 
induction of remission of CD, such as corticosteroids and anti-tumor necrosis factor (TNF) 
antibodies (4). The selection of an optimal treatment depends on several factors, including 
severity of disease, location, previous response to therapy, and co-morbidities.  
Historically, prior to the advent of biologic therapies, corticosteroids had been the most 
effective class of medication for treatment of acute flares of CD in adults (5) and children (6). 
Corticosteroids down-regulate the transcription of genes involved in pro-inflammatory 
cytokine production such as interleukin (IL)-1, IL-6, and NF-κB, and TNF and inhibit the 
expression of adhesion molecules in inflamed tissues and the trafficking of activated immune 
cells (7-9). Corticosteroids have been used for the treatment of inflammatory bowel disease 
since the 1950s (10). In a pivotal trial Truelove and Witts showed that oral cortisone at a 
dose of 100 mg daily effectively induced remission in patients with active ulcerative colitis 
(10). In patients with CD, corticosteroids are used to induce remission in moderate-to-severe 
ileo-colonic disease, extensive small bowel disease and pure colonic disease (11). 
Response to corticosteroids has been defined in several clinical studies as clinical 
improvement after treatment with high-dose oral corticosteroids (usually 40-60mg 
prednisone/d) within 30 days or clinical improvement after treatment with high-dose 
intravenous corticosteroids within 7-10 days (4, 12, 13). Conversely, patients who fail to 
respond to corticosteroids within this timeframe have been defined as corticosteroid 
refractory or corticosteroid resistant (4). Patients, who initially respond to corticosteroids but 
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then relapse with corticosteroid tapering or shortly after corticosteroid discontinuation and 
require reinstitution of corticosteroid therapy at doses of 10-30mg/d to maintain symptom 
control have been defined as corticosteroid dependent (4, 12). More than 50% of patients 
treated acutely with corticosteroids will become steroid dependent or steroid resistant (13-
17), particularly smokers, or those with colonic disease (18).  
Corticosteroids are characterized by several serious side effects that limit their use in 
the short and long term. Side effects can be classified as early, due to prolonged use or due 
to abrupt withdrawal (11), and daily use for more than 2-3 weeks significantly increases the 
risk of adverse events (19). The most common reported side effects are acne, arterial 
hypertension, hirsutism, striae, moon face, ecchymoses, cataracts, glaucoma, suppression 
of the adrenal function and infection (mainly increased risk of abdominal and pelvic abscess 
in CD patients) (1, 15, 20-22). Additionally, corticosteroids can induce a loss of bone mineral 
density and increase the risk of fractures (23-25). Owing to this significantly increased risk of 
osteoporosis, whenever corticosteroids are used in IBD patients, an initial baseline DEXA 
scan as well as supplementation of calcium and vitamin D are warranted once corticosteroid 
therapy is initiated (26-28). Other side effects which are associated include hyperlipidemia, 
hypokalemia, hyperglycemia and hypocalcemia (29, 30). In a multivariate analysis by 
Lichtenstein et al (31), the use of prednisone was associated with an increased risk of 
infection (OR 2.21, 95% CI 1.46-3.34, p< 0.001) and mortality (OR 2.10, 95% CI 1.15-3.83; 
p=0.016). Therefore, it is important to weight the risk-benefit ratio before use. In clinical 
practice, steroid-free remission represents an important primary end point in the treatment of 
CD patients.  
This review article focuses on the role of corticosteroids in inducing remission in adult 
patients with CD. It contains aspects such as approaches to steroid-sparing and minimizing 
the risk of steroid dependency, as well as the role of newer corticosteroids such as 
budesonide in reducing systemic side effects.  
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A literature search matching terms “prednisone”, “prednisolone”, “6-methylprednisolone”, 
and “budesonide” with the term “Crohn’s disease” was performed in the PubMed, Medline, 
the Cochrane Central Register of Controlled Trials, and EMBASE database. All relevant 
articles published in English and German between September 1960 and September 2013 
were reviewed.  
 
  
Conventional Corticosteroids 
a) Induction of Remission 
Conventional corticosteroids, such as prednisone, prednisolone, and 6-
methylprednisolone, are highly effective at inducing clinical remission in active CD (1, 15, 21) 
and are perceived as the most effective therapeutic option for inducing remission of mild to 
moderate CD. They can induce clinical remission in moderate-to-severe ileocaecal, colonic 
or small bowel CD as well as in oesophageal and gastric localizations in combination with 
proton pump inhibitors (4). For an overview of all randomized, double-blind placebo-
controlled trials please see Table 1. In a study by Summers et al (21), 162 patients with 
active CD (defined by a Crohn’s Disease Activity Index (CDAI) between 150 - 450) were 
randomized to receive placebo or prednisone (0.5-0.75mg/kg/day). Clinical remission with a 
CDAI < 150 was achieved at week 17 in 47% (40/85) in the patients receiving prednisone as 
compared to 26% (20/70) of patients receiving placebo (NNT=3).  
Malchow et al. included 223 patients (110 on placebo, 113 on 6-methylprednisolone 48mg/d) 
(15). After 1 week of methylprednisolone, the dose was gradually tapered to 12mg/d or 
placebo. The cycle of steroid treatment was repeated if remission was not achieved by week 
6 and 12. At week 18, the percentage of patients in clinical remission (CDAI < 150) was 83% 
and 37.9 %, respectively, for steroid treatment and placebo (NNT=2).  
In a third study, Brignola et al treated 18 patients with methylprednisolone 0.25mg/kg/d or 
placebo (32). At 6 months, a relapse rate of 78% was observed in the placebo group as 
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compared to 11% relapse rate in the methylprednisolone group. Several studies compared 
the benefit of corticosteroids over 5-ASA medications for induction of remission. The two 
early studies by Summers et al (using sulfasalazine at the equivalent of 2g/d of 5-ASA) and 
Malchow et al (using sulfasalazine at the equivalent of 1.2g/d of 5-ASSA) had both 5-ASA 
arms in their study protocol (15, 21). At lower 5-ASA concentrations corticosteroids revealed 
a clear benefit over 5-ASA therapy (15, 21, 33, 34). Studies comparing corticosteroids and 
higher doses of 5-ASA (3 to 4.5 g/d) did not show a benefit of corticosteroids, although long-
term follow-up was not available (34-37).  
Corticosteroids are important drugs in inducing clinical remission. They also have a limited 
capacity to induce mucosal healing or at least endoscopic improvement. Two studies 
showed a 29% rate of endoscopic remission with corticosteroid therapy (38, 39). Similarly, 
limited efficacy has been shown in patients with complicated CD. The presence of 
structuring and penetrating disease is likely to respond poorly to corticosteroids (16). Their 
use in cases of fistulizing disease is also limited due to evidence of an increased need for 
surgery (40, 41) and death occurring due to septic complications (15).   
No appropriate dose-ranging studies have been performed to evaluate steroid dosing or 
dose schedules for CD. Comparable clinical effects have been reported from placebo-
controlled and active-comparator trials with approximately 50-70% of patients achieving a 
clinical remission over 8-17 weeks receiving the equivalent of prednisone, 0.5-0.75 mg/kg (or 
40 mg/d) daily (21, 42-44). Higher doses of prednisone (1 mg/kg/d) or methyl prednisolone 
(1mg/kg/d) have demonstrated slightly higher response rates of 80-90% (15, 38). Several 
studies have also studied dexamethasone and betamethasone in CD patients, but this will 
not be the main focus of this review (45-47). 
 
b) Maintenance of Remission 
Conventional corticosteroids are not indicated for maintaining remission of CD due to their 
lack of efficacy and the potential multitude of systemic side effects (2). One small study 
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reported methylprednisolone to be more beneficial than placebo at maintaining remission 
(32). This result could not be reproduced in two larger studies and one smaller study 
comparing prednisone and 6-methylprednisonolone with placebo (15, 21, 48). The study by 
Summers et al. (The National Cooperative Crohn’s Disease Study) reported that 
0.25mg/kg/day was not effective at a 2-year follow-up at preventing relapses among patients 
in remission (21). The study by Malchow et al. (the European Cooperative Crohn’s Disease 
Study) determined that 6-methylprednisolone 48mg/d once daily was not better than placebo 
at maintaining remission at 2 years (15). In the study by Smith and colleagues from Cardiff, 
Wales, prednisone 7.5 mg/d or placebo was given to 64 CD patients with no beneficial effect 
regarding clinical relapse (48). In summary, a Cochrane Database Review concluded that 
conventional corticosteroids were not an effective maintenance therapy for up to 2 years 
(49). Therefore, long-term use of corticosteroids should be avoided and an introduction of 
steroid-sparing agents such as azathioprine or 6-mercaptpurine should be favoured (50-52).   
 
Non-systemic Corticosteroids (Budesonide) 
a) Induction of Remission 
More recently, topically-active formulations of corticosteroids such as budesonide have been 
developed in order to reduce systematic availability and adverse events while maintaining 
efficacy. Budesonide is a locally acting, topically delivered corticosteroid that undergoes 
extensive first-pass hepatic metabolism (80-90%) and accordingly, has low systemic 
absorption (53). Thus, the benefits of corticosteroids in managing mild to moderate CD can 
be achieved with a reduced risk of systemic adverse effects. Both, the ECCO and the AGA 
recommend budesonide as a first-line therapy for mild to moderate CD of the ileum and 
proximal colon (4, 26). For patients with CD, two formulations that target the ileocaecal tract 
have been formulated: pH-dependent (Budenofalk ® or Budeson ® - Dr. Falk Pharma, 
Freiburg, Germany) and controlled ileal release (Entocort ® - Astra Zeneca). The current 
literature is summarized in Table 2.  
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Budesonide vs. placebo: Several studies have been published on induction of remission of 
CD with budesonide. The two main studies showing the superiority of budesonide compared 
to placebo and inducing clinical remission in patients with active luminal disease are the 
ones by Greenberg et al. and Tremaine et al. (54, 55). Both trials included patients with 
terminal ileal, ileocolonic, or right-sided colonic CD. Greenberg at al reported that 
budesonide 9 mg/day for 8 weeks was significantly more effective than placebo at induction 
of remission in active CD (51 % vs. 20 %, respectively, p<0.001) (54). Tremaine et al found 
that budesonide 9 mg/day for 8 weeks resulted in remission in 48% of active CD patients but 
was not significantly different from placebo due to a high remission rate of 33% in the 
placebo-treated patients (p<0.05) (55). When those two trials were summarized in a 
metaanalysis, a clear statistically significant effect in favour of budesonide could be found 
with a NNT=5 (Budesonide achieving remission in one patient) (56).  
Budesonide vs. corticosteroids: Further 8 RCTs have compared the efficacy of 
budesonide with oral systemic corticosteroids or beclomethasone dipropionate. All trials 
recruited patients with distal ileal, ileocecal, or right-sided colonic CD, but most did not report 
exact patient numbers according to disease location. The remission rates in these studies 
were 51-60 % in the budesonide group and 52-89 % in the corticosteroid group (42, 43, 57-
62). The results of these trials have been summarized in two Cochrane Reviews and show 
that budesonide is comparable to prednisone in inducing clinical remission in patients with 
ileo-colonic CD (63, 64).  
Budesonide vs. 5-ASA: Only one study reported on induction of remission of budesonide 
vs. mesalazine. In this study, budesonide 9mg/d was a more effective induction therapy than 
mesalazine 4 g/d (65). A meta-analysis showed that budesonide induces more frequently 
remission than placebo or 5-aminosalicylic acid with an odds ratio of 1.85 in favour of  
budesonide vs. placebo (66).   
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Mantzaris et al. found that endoscopic remission was achieved in only 24% of patients 
administered budesonide compared to 83% administered with azathioprine (p<0.01), 
indicating that immunomodulators are more effective than budesonide in achieving mucosal 
healing (67).  
Thus, budesonide is safe and effective as an induction therapy for mild to moderate 
CD involving the terminal ileum and the proximal colon. 
 
b) Maintenance of Remission 
Budesonide is superior to placebo for CD remission and it is well tolerated even if it is taken 
for up to 1 year (68). However, budesonide is not prolonging  the time to relapse in CD 
patients. This has been investiagated in several studies, summarized in Table 3.  
Budesonide is not the drug of choice for maintenance of remission. This observation is 
based on a pooled analysis of five trials (69-73). All trials evaluated patients with quiescent 
luminal disease at 52 weeks. Those five trials have been summarized in a systematic review 
and meta-analysis (56). No statistically significant difference could be detected between 
budesonide and placebo in terms of prevention of relapse (RR=0.93; 95% CI 0.83-1.04). 
Similar results were published in a Cochrane study (34) and in a meta-analysis (74).  
In summary, budesonide is not significantly more effective than placebo (34, 54, 70-
73, 75-77) or systemic corticosteroids (78) in maintaining clinical remission in CD. 
 
Other agents 
Two additional substances should be mentioned only briefly as those were not the scope of 
this review. One is a novel formulation of budesonide which has recently been developed. It 
uses the multimatrix delivery system (MMX®), a special drug-release system characterized 
by a pH-dependent hydrophilic and inert matrix that acts as a gastroprotective layer, allowing 
release of the drug only when pH rises above 7. Therefore, it targets the entire colon and 
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could be used in colonic CD (79-81). The second agent is beclomathasone dipropionate 
(BDP). It is a topical-acting corticosteroid that is administered as a pro-drug with a rapid first-
pass effect (82). Only limited data is available. One study showed superiority of budesonide 
over BDP with remission rates at 8 weeks of 86.6% vs. 66.6% (p<0.001) (62).  
 
 
Approaches to Steroid-Sparing and Minimizing the Risk of Steroid Dependency 
Azathioprine and 6-mercaptopurine. 6-mercaptopurine and its pro-drug azathioprine are 
purine analogues that competitively interfere with nucleic acid metabolism by acting as 
substrate competitive antagonists for the hypoxanthine-guanine phosphoribosyl-transferase 
enzyme (83). Consequently both drugs have immune modifier properties by reducing the cell 
proliferation. Both drugs have been used successfully to treat patients with active, steroid-
refractory, and steroid-dependent inflammatory Crohn’s disease, and patients with fistulizing 
Crohn’s disease (84). In some azathioprine and 6-mercaptopurine studies steroid sparing 
effect of therapy was a primary outcome (85-89). It was assessed variously as (i) the ability 
to follow pre-defined steroid tapering regimen, and (ii) as the ability to reduce steroid dose to 
< 10 mg/day while maintaining remission. In the five studies reporting data on reduction of 
steroid consumption patients with active disease who received antimetabolite reduced their 
steroid consumption more significantly compared to placebo (85-88, 90). In a meta-analysis 
the pooled OR was 3.69 (95% CI 2.12-6.42) indicating a significant steroid sparing effect 
(84). The NNT to obtain a steroid sparing effect in one patient was 3. 
Anti-TNF-antibodies. In ACCENT I, 25 % of the patients who received 5mg/kg of infliximab 
and 34% of patients who received 10 mg/kg of infliximab were able to completely 
discontinue steroid therapy altogether and remain in remission (91). In the CHARM trial, 
35% of the randomized responders who received adalimumab 40mg every other week were 
off steroid therapy and in remission at week 26 compared to only 3 % of placebo patients 
(p<0.001). At week 56, 29 % of patients who received adalimumab 40mg every other week 
12 
were in remission off steroids compared to only 6 % of placebo-treated patients (p=0.008) 
(92). No comparable studies exist on certolizumab pegol.  
 
As mentioned above, over 50 % of patients become steroid-dependent or undergo 
surgery within one year of commencing therapy (14). Immunosuppressives and anti-TNF-
antibodies can reduce corticosteroid dependency and maintain disease remission and 
should therefore be considered early in the therapy.    
    
 
 
SUMMARY AND PRACTICAL TIPS 
Based on the NICE clinical guidelines, published in 2012, we will offer best practice advice 
on the care of patients with Crohn’s disease (93). Because corticosteroids are rapidly active 
and highly effective, they remain the mainstay for the induction of clinical remission of CD. If 
one needs to start with corticosteroids, use 0.5-0.75 mg/kg (or 40 mg/d) daily (21, 42-44). 
Offer whenever possible monotherapy with glucocorticosteroid (prednisolone, 
methylprednisolone or intravenous hydrocortisone) to induce remission especially in people 
with a first presentation or a single inflammatory exacerbation of Crohn’s disease in a 12-
month period (93). In people with one or more of distal ileal, ileocecal or right-sided colonic 
disease who decline, cannot tolerate or in whom a conventional glucocorticosteroid is 
contraindicated, consider budesonide for a first presentation or a single inflammatory 
exacerbation in a 12-month period. Explain to the patient however, that budesonide is less 
effective than a conventional glucocorticosteroid, but may have fewer side effects (93).  
Obviously, there is an increased concern about adverse effects associated with long-term 
conventional corticosteroid use, including suppression of the adrenal axis. Thus, clinicians 
must always consider a quick tapering of the dose and adverse events when using an 
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appropriate maintenance therapy. When a clinical response has been achieved, doses are 
tapered according to the rapidity and completeness of response. Generally, doses are 
tapered by 5-10 mg/week until 20 mg and then by 2.5-5 mg/week until discontinuation of 
therapy. In people who decline, cannot tolerate or in whom glucocorticosteroid treatment is 
contraindicated, consider 5-aminosalicylate (5-ASA) treatment for a first presentation or a 
single inflammatory exacerbation in a 12-month period. Explain that 5-ASA is less effective 
than a conventional glucocorticosteroid or budesonide, but may have fewer side effects than 
a conventional glucocorticosteroid (93). But always remember: do not offer budesonide or 5-
ASA treatment for severe presentations or exacerbations (93).  
In summary: within the changing landscape of available treatments in Crohn’s disease, 
glucocorticosteroids still remain an important therapy regardless of short- and long-term side 
effects.   
 
Key Point Summary: 
• For induction of remission with glucocorticosteroids in a CD flare start with 
corticosteroids 0.5-0.75 mg/kg (or 40 mg/d) daily 
• Due to short- and long-term side effects of glucocorticosteroids quick tapering is 
recommended (e.g. 5-10 mg/week until 20 mg and then by 2.5-5 mg/week until 
discontinuation of therapy) 
• Topically-active formulations of corticosteroids such as budesonide should be used in 
mild and moderate flares.  
 
 
 
Title for tables: 
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Table 1: Overview of randomized controlled trials of conventional corticosteroids in the 
treatment for Crohn’s disease.  
 
Table 2: Overview of randomized double-blind controlled trials of budesonide in induction of 
remission for Crohn’s disease.   
 
Table 3: Overview of randomized double-blind controlled trials of budesonide in maintenance 
of remission for Crohn’s disease.  
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Reference Year Type of 
study 
Total number of 
patients 
Drugs administered Study 
population 
Duration 
of Study 
(Weeks) 
Primary end point Remission rate 
% 
p-value 
Corticosteroids vs. placebo 
Summers19 1979 pc RCT 162 (77 placebo, 85 
prednisone) 
(1) prednisone 
0.25mg/kg/d (up to 0.75 
mg/kg/d)  
(2) sulfasalazine 
1g/15kg to a max of 
5g/d 
 (3) AZA  
(4) placebo 
CD patients 
followed by the 
National 
Cooperative 
Crohn's Disease 
Study (NCCDS), 
USA; 14 sites  
12 months clinical remission 
(CDAI<150) 
Prednisone 47% 
(40/85) remission, 
placebo 26% 
(20/77) remission at 
week 17 
0.0004 
Malchow15 1984 RCT, 
placebo 
105 (58 placebo, 47 
6-
methylprednsione) 
(1) 6-methylprednisone 
48mg/d (tapered over 6 
weeks)  
(2) sulfasalazine 3g/d  
(3) combination 
sulfasalaine plus 
corticosteroids  
(4) placebo 
CD patients 
followed by the 
European 
Cooperative 
Crohn's Disease 
Study (ECCDS), 
Europe, 15 sites 
24 months clinical remission 
(CDAI<150) 
Prednisone 83% 
(39/47) remission, 
placebo 37.9% 
(22/58) at week 18 
<0.001 
Brignola30 1988 RCT, 
placebo 
18 (9 placebo, 9 
methylprednisolone) 
methylprednisolone 
0.25mg/kg/d 
CD patients, 
single center 
6 months Relapse rate (CDAI 
increase of > 100 and 
over 150 for 2 
>weeks) 
Methylprednisone 
11% relapse (1/9), 
placebo 78% 
relapse (7/9) 
n.a.  
Corticosteroids vs. 5-ASA 
Scholmerich 1990 db RCT 62 (30 mesalazine, 
32 6-
(1) 6-
methylprednisolone 
CD patients, 
Germany and 
24 weeks insufficient efficacy 
(fever > 39°C over six 
(1) 
Methylprednisolone 
n.a. 
31 methylprednisolone) 48mg/d tapered over 
24 weeks ( 
2) mesalazine 2g/day 
for 24 weeks 
Austria days, increase CDAI 
> 350, increase 
CDAI>50 points since 
last visit, decrease of 
CDAI of less than 60 
points and van Hees 
Index < 30 points at 
week 4, or CDAI > 
150 and van Hees 
Index > 200 at week 
12 
65.5% (21/32) (2) 
mesalazine 26.7% 
(8/30) 
Martin34  1990 RCT 50 (28 prednisone, 
22 mesalamine) 
(1) oral prednisone 40 
mg/d for 2 weeks 
followed by a 4mg/d 
weekly reduction for a 
total of 12 weeks  
(2) Mesalamine 1g 3x/d 
for 12 weeks 
CD patients, 
Canada, 8 sites 
12 weeks clinical remission 
(CDAI<150) 
(1) prednisone 
42.8% (12/28) (2) 
mesalamine 40.9% 
(9/22) 
n.s.  
Gross33 1995 mc, dd 
RCT 
31 (16 6-
methylprednisolone, 
15 mesalamine) 
(1) 6-
methylprednisolone 
48mg/d tapered over 8 
weeks  
(2) mesalazine 1.5g 
3x/day for 8 weeks 
CD patients , 
Germany 
8 weeks clinical remission 
(CDAI<150) 
 
(1) 6-
methylprednisolone 
56.7% (9/16) (2) 
mesalazine 40% 
(6/15) 
 
0.5867 
 
Prantera35 
 
1999 
 
db, dd,  
 
94 (31 6-
methylprednisolone, 
35 mesalamine, 28 
mesalamine 
microgranular 
coated with 
Eudragit S) 
 
(1) oral 6-
methylprednisolone 
40mg/d in three doses, 
then tapered by 4mg/d 
every week for 12 
weeks  
(2) mesalamine 4g/d in 
three doses for 12 
CD patients, Italy, 
14 sites 
 
12 weeks 
 
clinical remission 
(CDAI<150) 
 
(1) 6-
methylprednisolone 
61 % (19/31) (2) 
mesalazine tablet 
60% (21/35) (3) 
mesalazine 
granules 79% 
(22/28) 
n.s. 
 
weeks  
(3) mesalamine 
microgranules coated 
with Eudragit 4g/day in 
three doses/d for 12 
weeks 
 
pc= placebo controlled, RCT= randomized controlled trial, db= double-blind,  mc= multi-center, dd= double-dummy 
Reference Year Type of 
study 
Total 
number 
of 
patients 
Drugs administered Study 
population 
Duration 
of Study 
(Weeks) 
Primary end point Remission 
rate % 
p-value 
budesonide vs. placebo 
Greenberg53 1994 db, pc 
RCT 
258 (1) Budesonide 3mg (67)  
(2) 9mg (61) 
(3) 15mg (64) 
(4) placebo (66) 
active CD, 
Canada, 27 sites 
8 clinical remission 
(CDAI<150) 
(1) 33  
(2) 51  
(3) 43  
(4) 20 
(1) 0.13  
(2) < 0.001  
(3) 0.009 
Tremaine54 2002 db, pc, 
RCT 
200 (1) Bud 4.5mg 2x/d 80  
(2) Bud 9mg 1x/d (79)  
(3) placebo (41) 
mild-to-moderate 
CD (CDAI 200-
450), USA, 24 
sites 
8 clinical remission 
(CDAI<150) 
(1) 53  
(2) 48  
(3) 33 
< 0.05 
budesonide vs. corticosteroid 
Rutgeerts41 1994 db, pc, 
RCT 
176 (1) Bud 9 mg for 8 weeks, then 
6mg for 2 weeks (88)  
(2) Prednisolone 40 mg for 2 
weeks, 30mg for 2 weeks, 25 
mg for 2 weeks, then taper by 
5mg/week (88) 
active ileal or 
ileocecal CD, 
Europe, 11 sites 
10 clinical remission 
(CDAI<150) 
(1) 53  
(2) 66 
0.12 
van Ierssel58 1995 db, dd, 
RT 
18 (1) Bud 9 mg for 8 weeks, then 
6mg for 2 weeks (9)  
(2) Prednisolone 40 mg for 2 
weeks, then taper by 5mg/week 
(9) 
active CD, 
Holland, 1 site 
10 effect on peripheral 
blood NK activity 
(1) 56  
(2) 89 
n.a. 
Gross57 1996 db, dd, 
pc RCT 
67 (1) bud 3x 3mg/d (34)  
(2) Mpred 48mg for 1 week, then 
32 mg/d for 1 week, then 
24mg/d for one week, then 
tapered by 4mg/week to 8mg/d 
(33) 
active CD, Austria 
and Germany, 8 
sites 
8 clinical remission 
(CDAI < 150) at week 
8 or clinical response 
(delat CDAI >60 oints 
if CDAI at entry < 
210) 
(1) 55.9 
(2) 72.7 
0.237 
Campieri42 1997 db, dd, 
pc RCT 
178 (1) bud 4.5 mg 2x/d (61)  
(2) Bud 9mg 1x/d (58)  
(3) Pred 40 mg (58) 
active CD, 
multinational, 26 
sites 
12 clinical remission 
(CDAI < 150)   
(1) 42  
(2) 60  
(3) 60 
0.062 
Bar-Meir56 1998 db, dd, 
RCT 
201 (1) Bud 3x 3mg/d (100)  
(2) Pred 40mg/d for 2 weeks, 
then 30 mg/d for 1 week, then 
tapered by 5mg/week (101) 
mild-to-moderate 
CD (CDAI 200-
450), Israel, 14 
sites 
8 response without 
steroid-related 
adverse events (Delta 
CDAI >60 points if 
CDAI at entry < 210) 
(1) 51  
(2) 52.5 
n.a.  
D'Haens60 1998 RT 29 (1) Bud 9mg/d (16)  
(2) Mpred 32mg/d, tapoered by 
4mg/week (13) 
active CD 
(CDAI>200), 
Leuven, Belgium 
10 parameters of bone 
turnover 
n.a.  n.a.  
Escher59 2004 db, dd 
RT 
48 (1) Bud 9 mg, tapered to 6mg/d 
(22)  
(2) Pred 1mg/kg, tapered to 
2.5mg/d (24) 
pediatric active 
CD (CDAI>200), 
Europe, 36 sites 
12 clinical remission 
(CDAI < 150) 
(1) 55  
(2) 71 
0.25 
Tursi61 2006 non-
blinded 
RT 
30 (1) Bud 9 mg (15) 
 (2) Beclomethasone 10 mg/d 
(15)  
mild-to-moderate 
CD (CDAI 150-
250), Italy, 3 sites 
8 clinical remission 
(CDAI < 150) 
(1) 66.7  
(2) 53.3 
< 0.001 
budesonide vs. mesalamine 
Thomsen64 1998 db RCT 182 (1) Bud 9 mg/d (93)  
(2) mesalamine 2x 2g/d (89) 
active CD (CDAI 
200-400), Europe, 
South Africa, 
Australia, 25 sites 
16 clinical remission 
(CDAI < 150)   
(1) 62  
(2) 36 
< 0.001 
db=double-blind, pc= placebo-controlled, RCT= randomized controlled trial, dd= double-dummy  
Reference Year Type of 
study 
Total 
number 
of 
patients 
Drugs administered (n) Study 
population 
Duratio
n of 
Study 
(Weeks) 
Primary end point Remission rate 
% 
p-value 
budesonide vs. placebo 
Greenberg67 1996 db RCT 105 (1) Bud 3mg/d (33)  
(2) Bud 6 mg/d (36) 
 (3) placebo (36) 
Canada, 23 sites 52 maintenance of remission, 
relapse defined as CDAI 
remaining at > 150 and a 
minimum increase of 60 
points 
Relapse rate  
(1) 70%  
(2) 61% 
 (3) 67% 
0.75 
Lofberg68 1996 db RCT 90 (1) Bud 3mg/d (31)  
(2) Bud 6 mg/d (32) 
(3) placebo (27) 
Europe, 11 sites 52 maintenance of remission, 
relapse defined as CDAI 
remaining at > 150 and a 
minimum increase of 60 
points from entry 
Relapse rate  
(1) 74%  
(2) 59% 
(3) 63% 
0.44 
Ferguson70 1998 db RCT 75 (1) Bud 3mg/d(26)   
(2) Bud 6 mg/d (22)  
(3) placebo (27) 
Europe and 
Australie, 20 sites 
52 maintenance of remission, 
relapse defined as CDAI 
remaining at > 150 and a 
minimum increase of 60 
points from entry 
Relapse rate (1) 
46% (2) 48% (3) 
60% 
n.s.  
Gross69 1998 db, RCT 179 (1) Bud 3 mg/d (84  
(2) placebo (95) 
Germany, 8 sites 52 maintenance of remission, 
relapse defined as CDAI 
remaining at > 150 
Relapse rate  
(1) 67% (56/84)  
(2) 65% (62/95) 
n.s. 
Hanauer71 2005 db, pc 
RCT 
110 (1) Bud 6mg/d (54)  
(2) placebo (54)  
USA, 22 sites 52 time to relpase (CDAI > 150 
plus increase of at least 60 
points) 
Median time to 
relpase  
0.132 
(1) 360 days  
(2) 169 days 
db= double-blind, RCT= randomized controlled trial, pc= placebo-controlled  
